<?xml version='1.0'?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:georss="http://www.georss.org/georss" xmlns:atom="http://www.w3.org/2005/Atom"  xmlns:media="http://search.yahoo.com/mrss/">
<channel>
	<title><![CDATA[0xbt: Sansom's groups]]></title>
	<link>https://0xbt.net/groups/member/ElizaBlock</link>
	<atom:link href="https://0xbt.net/groups/member/ElizaBlock" rel="self" type="application/rss+xml" />
	<description><![CDATA[]]></description>
	
	<item>
	<guid isPermaLink="true">https://0xbt.net/groups/profile/8365653/sanofi-confirms-32-bln-offer-to-buy-us-biotech-firm-translate-bio</guid>
	<pubDate>Thu, 25 Aug 2022 16:11:26 +0000</pubDate>
	<link>https://0xbt.net/groups/profile/8365653/sanofi-confirms-32-bln-offer-to-buy-us-biotech-firm-translate-bio</link>
	<title><![CDATA[Sanofi Confirms $3.2 Bln Offer To Buy U.S. Biotech Firm Translate Bio]]></title>
	<description><![CDATA[<p>PARIS, Aug 3 (Reuters) - French drugmaker Sanofi said it had made a $3.2 billion offer to buy U.S.
biotech company Translate Bio, as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.</p><p>In a statement that confirmed an exclusive report by Reuters, Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash,  <a href="https://healthtopical.com/does-bio-oil-remove-stretch-marks">healthtopical.com</a> representing a total equity value of about $3.2 billion for Translate Bio.</p><p>The boards of both companies had approved the deal, the firm added.</p><p>"Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics," Chief Executive Paul Hudson said.

<i><span style="text-decoration: underline;">(Reporting by Matthias Blamont and Sudip Kar-Gupta; Editing by Clarence Fernandez)</span></i></p>]]></description>
	<dc:creator>Sansom</dc:creator>
</item>

</channel>
</rss>